Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Resistance to four HIV drug classes is tied to high risk of disease and death.
This finding among sub-Saharan Africans is quite concerning since dolutegravir is now the preferred first-line HIV treatment worldwide.
This finding comes from a small study of people with highly resistant HIV.
Black study participants switched from a regimen with two nucleoside/nucleotide reverse transcriptase inhibitors plus one other HIV drug.
Extended follow-up confirms that the long-acting monoclonal antibody works well for people with highly resistant HIV.
The novel attachment inhibitor led to viral suppression in 60% of people with extensive prior treatment.
A handful of such cases have been reported since Truvada was approved as pre-exposure prophylaxis in 2012.
Researchers are surprised and concerned that a strain of HIV that is so broadly resistant to treatment even has the capacity to transmit.
A recent analysis suggested that only one in four people on antiretroviral treatment take 95% or more of their doses.
ViiV applies for FDA approval of HIV drug fostemsavir
In a recent small study, resistance was limited to the emtricitabine component of Truvada and did not seem a major cause for concern.
Gilead’s HIV capsid inhibitor might need dosing only every six months
A recent survey found that pharmacies are insufficiently educating the public about unused opioid and antibiotic disposal.
Expanded access study confirms the long-acting monoclonal antibody works well in people with extensive prior treatment.
The attachment inhibitor performed well as an adjunct to an optimized antiretroviral regimen among those with multidrug-resistant HIV.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.